Principles and use of anti-CTLA4 antibody in human cancer immunotherapy (Q36389992)

13 August 2017

1 reference

title

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy (English)

1 reference

13 August 2017

1 reference

1 reference

4

James P Allison

0 references

Sergio A Quezada

object named as

Sergio A Quezada

series ordinal

2

0 references

author name string

Karl S Peggs

series ordinal

1

1 reference

13 August 2017

Alan J Korman

series ordinal

3

1 reference

13 August 2017

publication date

7 February 2006

1 reference

Current Opinion in Immunology

13 August 2017

published in

1 reference

13 August 2017

volume

18

1 reference

13 August 2017

issue

2

1 reference

13 August 2017

page(s)

206-213

1 reference

Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses

13 August 2017

cites work

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

In vivo overexpression of CTLA-4 suppresses lymphoproliferative diseases and thymic negative selection

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

The B7 family revisited

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

B7-independent inhibition of T cells by CTLA-4.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

The immunobiology of cancer immunosurveillance and immunoediting

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

Enhancement of antitumor immunity by CTLA-4 blockade

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via T-T interactions [corrections].

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

Modulation of tryptophan catabolism by regulatory T cells.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

The interaction properties of costimulatory molecules revisited.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

Structural analysis of CTLA-4 function in vivo

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

Molecular interactions mediating T cell antigen recognition

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

CTLA-4: new insights into its biological function and use in tumor immunotherapy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.COI.2006.01.011

Durable responses and long-term progression-free survival observed in a phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma

1 reference

18 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1200/JCO.2005.23.16_SUPPL.7525

Identifiers

DOI

10.1016/J.COI.2006.01.011

1 reference

13 August 2017

1 reference